June 2, 2021
The DOE Office of Science program in Isotope R&D and Production (DOE IP) has announced a new funding opportunity for research to facilitate, streamline, and accelerate the translation of novel radioisotopes and their associated chelating agents and linker/ligands, for both diagnosis and treatment, from the laboratory bench to evaluation for potential usage in clinical and pre-clinical trials.
Successful applications would benefit the public by leveraging the scientific and technical capabilities of existing facilities at institutions of higher education, non-profit research institutions, and DOE/National Nuclear Security Administration (NNSA) National Laboratories to accelerate the development process for new diagnostic and therapeutic agents.
Applications are restricted to recently developed medical isotopes by the DOE IP but are not restricted in chelator/ligand technology. Applications incorporating effective ways to train personnel with essential knowledge and skills related to the production, processing, purification, and distribution of enriched stable and radioactive isotopes are strongly encouraged.
For more information, see the full announcement.